Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ICAD - Up 5% Pre-Market/ Current Price $2.06
Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
its taking a breather for you to hop in!!
Give us time to load ;) $iCAD
moving in the right direction ...
$iCAD looking forward to the start of quarter over quarter growth, the relationship with Google and also GE Healthcare just became there own company.
On Dec. 5, U.S. stocks were dragged down in part by renewed bearishness on the part of Morgan Stanley (NYSE:MS) analyst Mike Wilson. However, with the U.S. services sector, the job market, and consumer spending holding up quite well, it’s difficult for me to imagine how the profit collapse predicted by Wilson could materialize. Actually, it’s hard to believe that the earnings of many companies won’t be stronger than expected. Especially if oil prices stay at their current, low levels and overall inflation continues to retreat. Given these points, I think that investors should use the latest decline as an opportunity to buy a number of the best Nasdaq stock picks for 2023 that I will list below.
In addition, I’d take Wilson’s warning with a grain of salt. In June, Wilson suggested that U.S. earnings would plunge. Also worth noting is that, in late June 2022, Wilson suggested that U.S. earnings would plunge, noting, “We see a pretty poor risk reward over the next 3-6 months with recession risk rising in the face of very stubborn inflation readings.” However, U.S. earnings haven’t plunged, and nearly six months later, the S&P 500 has risen 6% above its late June levels, even after yesterday’s slump that was partially induced by Wilson himself. (As of the morning of Dec. 1, the index had jumped nearly 9% above its late June levels). So contrary to popular belief, Wilson’s predictions have been far from perfect this year.
Again, I’d use the latest pullback as an opportunity to pick up some of the best NASDAQ stock picks for 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
TSLA
Tesla
$176.68
PLUG
Plug Power
$13.86
ICAD
iCAD
$1.71
SHLS
Shoals Technologies
$24.47
EXPE
Expedia
$96.24
UAL
United Airlines
$45.42
WDAY
Workday
$160.88
Tesla (TSLA)
?
Tesla (TSLA stock) Motors store in Piazza Gae Aulenti square in Milan, Italy
Source: Zigres / Shutterstock.com
Tesla’s (NASDAQ:TSLA) shares slumped on reports the company would reduce production of its Model Y EV by 20% at its Shanghai plant from Nov.
However, Tesla forcefully denied the report. Even if the news is true, it doesn’t mean that the company’s overall sales growth is slowing. As Barron’s pointed out, Tesla could have decided to reduce production of its Model Y and increase production of one of its other EVs instead. Also possible is that Tesla decided to cut production in China and raise production at another one of its factories simultaneously. In my view, other news involving Tesla and TSLA stock is much more critical. Specifically, the forward price-earnings ratio of TSLA stock, which dropped to just 35.8. That’s very low for a company which is the runaway leader of a booming market.
Finally, Tesla recently made the first deliveries of its full-size truck, the Tesla Semi. Since the EV, according to TSLA, “has triple the power [of] any diesel truck on the road right now.” and can haul a full load 500 miles one one charge, I believe that it will become a major revenue generator for the automaker.
Plug Power (PLUG)
?
Nasdaq in focus accompanied by a green arrow and the word "NYSE"
Source: Shutterstock
Plug Power (NASDAQ:PLUG) continues to make meaningful progress as it seeks to solidify its position as a leader in the green hydrogen revolution. As PLUG opens more of its green hydrogen factories, its margins are poised to meaningfully rise. That’s because the company can produce green hydrogen at its own plants at less cost. Also, the large tax credit for green hydrogen should also be a game changer for PLUG next year. As a result of these upcoming, positive catalysts, the company predicts that its 2023 revenue will come in at $1.4 billion.PLUG also expected to generate “breakeven operating margins” by the end of next year.
On other fronts, Plug Power’s joint venture with Renault, the giant European automaker, is expected to ramp up next year, as the venture is poised to produce and deliver 800 vans in 2023. Also noteworthy is that Plug Power’s partner, Airbus (OTC:EADSY), the huge European plane manufacturer, recently announced “that it is developing a hydrogen-powered fuel cell engine.” The company intends to begin conducting trials of the engine around 2025 , and the company plans to start building new aircraft that may utilize hydrogen in five to six years.
Consequently, within a year or two, it could become apparent that Airbus is going to buy a large amount of hydrogen from Plug Power. As a result, PLUG stock could very well get a huge boost between the end of 2023, sometime in 2024, or even sooner. As Plug’s potential comes into clearer view next year, PLUG stock should rise dramatically, making the shares one of the best Nasdaq stock picks for 2023.
iCAD (ICAD)
?
Bright signs for Nasdaq (NDAQ) cover the Nasdaq building in Times Square.
Source: Shutterstock
A developer of artificial intelligence-driven products used to detect cancer, iCAD (NASDAQ:ICAD) recently announced that it had reached a deal with Alphabet’s (NASDAQ:GOOG,NASDAQ:GOOGL) Google Health. Under the agreement, Google Health’s AI will be incorporated “into iCAD’s portfolio of breast imaging AI solutions.”
The deal will constitute the introduction of Google’s breast imaging AI into clinical practice. Moreover, Google agreed to license its AI tevchnology to iCAD. Over the longer term, the deal should be a game changer for iCAD and ICAD stock. First, in the eyes of investors and potential customers, Alphabet’s decision to partner with iCAD should validate iCAD’s technology. Secondly, since Google Health is licensing its technology to iCAD, Alphabet should benefit financially from the proliferation of iCAD’s “breast AI technologies.” As a result, Alphabet is likely to use its huge sales force, gigantic network of contacts, and large amounts of money to boost the sales of iCAD’s tevhnologies.
Trading with a bargain-basement market capitalization of just $43.57 million and just 1.5x sales, iCAD stock does not appear to reflect any of these opportunities.
Shoals Technologies (SHLS)
?
conceptual image of the word NASDAQ surrounded buy red stock chart action
Source: Shutterstock
A developer of components used in solar-energy projects, Shoals (NASDAQ:SHLS) should get a big lift from two recent decisions made by the Biden Administration. Specifically, the administration found that four Chinese solar panel makers did not seek to avoid tariffs by opening factories in nearby Asian countries. Also, in-line with my previous predictions, US Customs and Border Protection released a major proportion of the solar panels hat it had been impounding in response to the Uyghur Forced Labor Prevention Act. The panels were made by China’s JinkoSolar (NYSE:JKS).
Since the U.S. has been suffering from a shortage of solar panels, the moves by the administration should enable more large-scale solar projects to get underway in the country more quickly, reducing Shoals’ “backlog and awarded orders of $471.2 million” and boosting the company’s top and bottom lines. It’s probably not a coincidence that, since both of the Biden administration’s moves were reported on Dec. 2, SHLS stock has climbed nearly 10%. Finally, as I pointed out in a previous column, last quarter, Shoals’ “Revenue was up 52% year over year to $91 million,” and its “Gross margin expanded to 39.7%, up 330 basis points from a year ago, while adjusted earnings of 10 cents per share easily exceeded the 2 cents analysts were calling for.”
Expedia (EXPE)
?
Expedia app logo on a smartphone screen
Source: NYC Russ / Shutterstock.com
Expedia (NASDAQ:EXPE) reported very impressive third-quarter results. From here, the company should continue to benefit from the very strong, pent-up demand for travel well into 2023. Moreover, the valuation of EXPE stock remains very attractive. In Q3, Expedia’s top line climbed 22% year-over-year to a record $3.62 billion, while its operating income, excluding certain items, surged 42% YOY to $747 million. Also, in the first nine months of 2022, Expedia’s free cash flow soared over 100% to $3.1 billion. And the company’s Q3 lodging bookings also set an all-time record last quarter.
Moreover, EXPE CEO Peter Kern reported that the company would resume buying back its stock which the company views as “highly undervalued.” In addition, Wells Fargo (NYSE:WFC) said EXPE’s Q3 results had been “solid,” adding that it is pleased with the company’s loyalty and investment efforts. the firm maintained an “overweight” rating on EXPE.
United Airlines (UAL)
?
a jet takes off on a clear runway.
Source: m.photo / Shutterstock.com
United Airlines (NASDAQ:UAL) was named a top airline pick by Morgan Stanley, which tends to be one of the more bearish firms on the Street. Among the positive catalysts cited by Morgan Stanley analyst Ravi Shanker were a rebound in international travel and the new contract that United signed with its pilots. Shanker added that the airline’s, “Earnings recovery out of the pandemic has kept pace with, if not led, peers,” while widespread concerns about the company’s profitability have been laid to rest. “UAL seems on track to exceed its 2023 guidance and to hit its 2026 guide issued 18 months ago — something even the biggest UAL bulls may have considered difficult at the time.” In addition, analysts at Cowen also said the UAL stock is its top pick among airline stocks, citing the company’s high exposure to international flights.
Workday (WDAY)
?
software stocks: Coding software developer work with augmented reality dashboard computer icons of scrum agile development and code fork and versioning with responsive cybersecurityMore
Source: Shutterstock
Workday (NASDAQ:WDAY) provides software that helps companies manage their human resources and financial applications.
The company reported very strong third-quarter results on Nov. 29. Its revenue jumped 20% year-over-year to $1.6 billion and came in slightly above analysts’ average estimate. More impressively, its operating cash flow increased to $409 million, up from $385 million during the same period a year earlier, while it generated earnings per share of 99 cents, well ahead of analysts’ average estimate of 84 cents. “We are well-positioned in this type of [macro] environment because our cloud finance and HR solutions are truly mission-critical. As our Q3 results showed, more and more organizations are selecting Workday as their trusted partner to help them successfully navigate today’s changing world,” Workday CEO Aneel Bhusri said during the company’s Q3 earnings call.
Further, the company announced a new, $500 million share buyback plan. In a note to investors, investment firm Monness, Crespi, Hardt wrote that the company has “a large market opportunity” and is carrying out its initiatives well. However, the firm kept a “neutral” rating on the shares, citing macro issues. But, as I indicated in my introduction, I believe that worries about the macro issues are overdone.
On the date of publication, Larry Ramer owned shares of SHLS,JKS,ICAD and PLUG. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
It doesn’t matter if you have $500 or $5 million. Do this now.
The post Our 7 Top Nasdaq Stock Picks for 2023 appeared first on InvestorPlace.
?
Google Health Launches AI Partnership to Improve Breast Cancer Screening
Google Health has launched its first commercial agreement to license its mammography AI research model for integration into real-world clinical practice.
??
By Shania Kennedy on November 29, 2022
Google Health and mammography artificial intelligence (AI) vendor iCAD, Inc. announced a strategic partnership to integrate Google Health’s AI technology into iCAD’s portfolio of breast imaging AI solutions in an effort to improve breast cancer detection and assessment of short-term personal cancer risk.
This partnership is the first time Google Health has licensed its mammography research model, and according to a press release shared following Google’s announcement, iCAD will work toward validating and incorporating the tech giant’s mammography AI technology into its product portfolio for use in clinical practices. The two companies said they will also work together to enhance breast cancer AI solutions for mammography and expand access to these tools to millions of patients and providers worldwide.
RELATED ARTICLES
Hackensack Meridian Health to Leverage Google's New Medical Imaging Tool
Harvard, Stanford Develop Self-Supervised AI to Detect Disease Via X-ray
Geisinger Deploys AI Imaging Model to Diagnose Coronary Artery Disease
Sign up for our newsletter!
“Google Health is our cross-company initiative to use technology to help everyone, everywhere be healthier – and collaborating with leading-edge companies like iCAD is a key part of this strategy,” said Greg Corrado, PhD, Head of Health AI at Google, in the press release.
Under the collaboration, Google and iCAD will focus on advancing innovation and expanding access to mammography technology via cloud-based solutions, the press release states. Google Health’s AI technology is set to be integrated into iCAD’s Breast AI Suite, a portfolio of technologies for breast cancer detection, density assessment, and personalized short-term risk evaluation. By validating and integrating Google’s mammography tools into this portfolio, the agreement aims to support cancer patients’ journeys, the companies said.
iCAD is also set to incorporate Google’s mammography AI offerings into ProFound AI Risk, a clinical decision support tool designed to provide an accurate, personalized short-term breast cancer risk estimation. Using Google’s solutions, iCAD said it hopes to improve the performance of its algorithms for 2D and 3D mammography.
In addition to leveraging Google’s AI technology, iCAD will also use Google Cloud’s infrastructure to expand cloud-hosted mammography solutions into new regions and scale access to these tools in underserved areas, according to Google’s announcement.
“Healthcare providers are increasingly moving away from locally deployed systems in favor of virtual or remote settings,” said Stacey Stevens, president and CEO of iCAD, in the press release. “Additionally, hospitals are under increasing pressure to reduce costs, while providing higher quality care, underscoring the need to streamline operations and increase clinician productivity. Integrating Google’s Cloud technology into this more flexible delivery model offers facilities the solution they need, and the technology patients deserve.”
The partnership is also set to build on Google Health’s work in mammography.
In 2020, Google published research showcasing how one of its AI models was able to identify breast cancer in screening mammograms with greater accuracy, fewer false positives, and fewer false negatives than radiologists.
Using de-identified mammograms from over 3,000 patients in the US and 25,000 in the UK, the AI model produced a 5.7 percent reduction of false positives in the US, and a 1.2 reduction in the UK. The model also produced a 9.4 percent reduction in false negatives in the US and a 2.7 percent reduction in the UK.
Tagged Artificial Intelligence, Cancer Detection, Google, Imaging Analytics, Medical Imaging
Dig Deeper
Google Uses Artificial Intelligence to Detect Breast Cancer
Deep Learning Predicts Women’s Future Risk of Breast Cancer
Google Deep Learning Tool 99% Accurate at Breast Cancer Detection
Related Resources
Taking Control of ED Processes to Reduce Costs and Improve Patient Satisfaction
Chronic Disease Care: Essential AI for Health Plans
View on HealthITAnalytics
©2012-2022 TechTarget, Inc. Xtelligent Healthcare Media is a division of TechTarget. All rights reserved. HealthITAnalytics.com is published by Xtelligent Healthcare Media a division of TechTarget.
Hopefully this subscription model is a success but may take a few quarters to show the street something. Is there a white knight somewhere waiting to pounce? Looking forward to more glioblastoma study updates. Good buying opportunity at the moment. Go $iCAD
So now up to $4.50 per share and my options looking good! But what was the driver yesterday? It went up over 10% on no apparent news. M&A?
I would think that ICAD could be a BO target for either Varian or GE Healthcare.
Is ICAD a buy at $3.50? Analysts have the company being profitable in 1-2 years. More hospitals are adding the Xoft therapy system. Things may be looking up. I'm grabbing a few Dec options to start. I got the Dec $2.50 calls for $1.30. I'll double my money at about $5 per share.
Got out breakeven yesterday due to impending Death Cross at 11.50 .
Very nice , seems you nailed it!
Jumped in at 11.50 this morning after a the stock had a 40% haircut in part due to a revenue and earning miss. The cc transcript showed that the miss was due to longer sales cycle with their enterprise customers rather than a loss of those customers to the competition. Which should mean the sales should eventually happen. Margin expansion as well.
Looking for this stock to retest it's high near 20 in the next 12 months.
Breaking News: $ICAD iCAD Responds to CMS' Finalized Radiation Oncology Alternative Payment Model
NASHUA, N.H., Sept. 20, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publicat...
Find out more ICAD - iCAD Responds to CMS' Finalized Radiation Oncology Alternative Payment Model
JUST IN: $ICAD iCAD's IORT Excluded from CMS's Radiation Oncology Alternative Payment Model
Existing Reimbursement Codes Will Still Apply in All Geographic Markets iCAD Intends to Submit Additional Long-Term Data in Support of IORT’s Inclusion and Petition CMS for Reconsideration NASHUA, N.H., Sept. 18, 2020 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a g...
In case you are interested ICAD - iCAD's IORT Excluded from CMS's Radiation Oncology Alternative Payment Model
Let's get this party started then!
Very quiet board given the recent performance.
New 52 week high & 12 year high, impressive in this market !
Time to rev up this site now that iCAD has broken out in price on volume on a day when all major indices were down!
News: $ICAD iCAD Reports Second Quarter 2019 Financial Results
NASHUA, N.H., Aug. 01, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported financial results for the three and six months ended June 30, 2019. Second Quarter 2019 Highlight...
Got this from iCAD Reports Second Quarter 2019 Financial Results
News: $ICAD iCAD's ProFound AI(TM) for 2D Mammography Receives CE Mark Approval
NASHUA, N.H., July 11, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its advanced artificial intelligence technology and workflow solution, ProFound AI™ for 2D Mammog...
Got this from iCAD's ProFound AI(TM) for 2D Mammography Receives CE Mark Approval
News: $ICAD SimonMed Imaging Implements the First FDA-Cleared 3D Tomosynthesis Software Using Artificial Intelligence
PHOENIX and NASHUA, N.H., July 10, 2019 (GLOBE NEWSWIRE) -- SimonMed Imaging , one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced today their implementation of the first FDA-cleared AI program for significantl...
Read the whole news SimonMed Imaging Implements the First FDA-Cleared 3D Tomosynthesis Software Using Artificial Intelligence
iCAD has yet to be discovered as can be shown by the lack of messages on this board. I predict that they are soon to be discovered as a result of the success of the use of AI in their breast cancer detection software, and by 2020 will be able to give every individual women a personal assessment of their breast cancer odds for the next three years following examination.
This will likely explode the stock price!
News: $ICAD iCAD to Highlight ProFound AI(TM) Solution for Digital Breast Tomosynthesis at 2019 Society of Breast Imaging Annual Symposium
NASHUA, N.H., April 04, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will present its latest artificial intelligence software solution for digital breast t...
Find out more https://marketwirenews.com/news-releases/icad-to-highlight-profound-ai-tm-solution-for-digital-breast-tomosynthesis-at-2019-society-of-breast-imaging-annual-symposium-7946588.html
0.8 billion market cap
ICAD the big winner for team TREND this week and holding into next.
AI technology for cancer detection is very interesting. Looking for 5.88 here!
How much further do you expect this to continue to climb?
Breast cancer is a highly publicized health issue. Any progress will attract great attention here....as what seems to be happening now.
ICAD just a beautiful breakout on this bio beast!!!
$ICAD on the rise with imminent submission of FDA approval for PowerLook Tomo Detection 2.0!
https://www.otcmarkets.com/stock/ICAD/news/story?e&id=1081944
Looking forward to hearing when Powerlook Tomo 2.0 version will be submitted to the FDA.
I hear that ICAD and SSH are competitors?
I'm not too much familiar with ICAD but I hear that SSH has 5 upgrades and is going through FDA approval right now. I also see a new PR from SSH.
Can you please let me know about ICAD?
If anyone is interested in a great stock to invest in, they should check out SSH as they've several upgrades and they're working on their FDA approval.
$ICAD Chart - BULLISH HARAMI reversal pattern is forming today - EMA 8 @ 4.11 is the Key level to break -
http://www.candlesticker.com/Pattern.aspx?lang=en&Pattern=2102
BULLISH HARAMI
Definition
This pattern consists of a black body and a small white body that is completely inside the range of the black body. If an outline is drawn for the pattern, it looks like a pregnant woman. This is not a coincidence. “Harami” is an old Japanese word for “pregnant”. The black candlestick is “the mother” and the small candlestick is “the baby”.
positive moving up lots of room to move 7.13
$1.50 to $11.00+++ What a great Yr for ICAD!
Yes what a monster.
Smitter SMTT
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
150
|
Created
|
09/17/09
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads